Controversies & Advances in the Treatment of Cardiovascular Disease
  • Home
  • CME

Controversies 2019 Online Syllabus

General Course Materials
Course CME
Updated 2019
Program
General Symposium
Information
Faculty
Disclosures

Thursday, November 14, 2019

Session I: Atherosclerosis and Dyslipidemia

GUT Heart Axis: Potential Therapeutic Implications

W.H. Wilson Tang, MD, FACC
 
Aspirin in Primary Prevention: Who Should Get It?
Sanjay Kaul, MD, MPH, FACC
                                                                       
Targeting ANGPTL3 In Hyperlipidemia
P.K. Shah, MD, MACC
                                   

Keynote Lecture: Comprehensive Imaging in Heart Failure
Jeroen Bax, MD, PhD, FACC

Session II: Digital Medicine

Healthcare in the Age of Disruption
Raj Khandwalla, MD, MA, FACC
 
ACC Initiatives
John G. Harold, MD, MACC
 
Keynote Lecture: The Hospital Readmission Reduction Policy and Population Health in Heart Failure
Gregg Fonarow, MD, FACC
                                               
The Future of Healthcare Delivery
Sachin Jain, MD, FACC

Session III: Controversies in the Treatment of CAD: Expert Views

Complete Versus Incomplete Revascularization in STEMI and MV Disease: Is There Still a Debate?
Shamir Mehta, MD, MSc, FACC

State-of-the-Art: Optimal DAPT Strategies: Lessons Learned, Global Leaders, TWIGHLIGHT, and More
Roxana Mehran, MD, FACC

PCI in Selected Cases: EXCEL, NOBLE and Even Long Term SYNTAXES Show Similar Results
Roxana Mehran, MD, FACC
 
CABG in All Cases: More Durable, Better Outcomes!
Joanna Chikwe, MD, FRCS

Session IV: Update in Cardiac Imaging

Plaque Assessment on CCTA: Is There Clinical Value?
Damini Dey, PhD
 
Myocardial Blood Flow with PET: Added Clinical Value?
Timothy M. Bateman, MD, FACC
 
Debate: Is Diagnostic Cath Dead?
Jonathon A. Leipsic, MD, FRCPC
Bruce Samuels, MD, FACC

Session V: Structural Heart Disease

TAVR for Severe Aortic Stenosis After 17 Years: All Risk But Not All Patients
Michael Mack, MD, FACC

Should TAVR Be Standard for Bicuspid Aortic Stenosis, Or Do We Need a Randomized Clinical Trial?
Raj Makkar, MD, FACC

Transcatheter Mitral Valve Repair Should Be the Standard of Care for Functional Mitral Regurgitation
Michael Mack, MD, FACC

Transcatheter Mitral Valve Repair for Functional MR: What Should We Not Get Carried Away?
Sanjay Kaul, MD, MPH, FACC

Thoughts of a Heart Failure Specialist Who Deals with These Patients Every Day
Michele A. Hamilton, MD, FACC

Is Transcatheter Mitral Valve Repair Ready for Low-Risk Patients?
Joanna Chikwe, MD, FRCS

Session VI: Cardioembolic Strokes

Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-Term Prevention of Stroke
Tarun Chakravarty, MD, FACC

Paradigm Shift in Patient Selection for PFO Closure
Matthew J. Price, MD, FACC

Session VII: The Right Ventricle in 2019: Forgotten, But Not Forgiving

The Challenges in RV Function Assessment: Clinical and Imaging Strategies
Siddharth Singh, MD, MS

What to Do When Conventional Therapy for RV Failure is Unsuccessful?
Danny Ramzy, MD, PhD, FACC

Friday, November 15, 2019

Session VIII: Clinical Electrophysiology
 
Effective Management of Syncope in 2019
Win Shen, MD, FACC
 
Debate: Is Atrial Fibrillation Curable?
Atrial Fibrillation is Curable
Michael Shehata, MD, FACC
Once in Atrial Fibrillation, Always in Atrial Fibrillation
Eugenio Cingolani, MD

How to Approach the Patient with Defibrillator Shocks
Ashkan Ehdaie, MD
 
Session IX: Hypertension
 
Physician Inertia in Hypertension: Are Pharmacists the Better Doctors?
Florian Rader, MD, MSc, FACC

Keynote Lecture: CT Angiography and FFR-CT To Help Plan Coronary Interventions?
Jonathan Leipsic, MD, FRCPC

Session X: Controversies in Acute PULM Vascular Disease
                                             
Acute Intermediate-Risk (Submassive) Pulmonary Embolism Should be Treated with Anticoagulation Plus Aggressive Therapy Such as Catheter-Directed Approaches
• Pro – Victor Tapson, MD
• Con – Oren Friedman, MD
 
Keynote Lecture: The Perils of Digital Medicine
John Mandrola, MD, FACC
 
Keynote Lecture: Anticipated Changes in Healthcare Policy Over the Next Few Years
Scott Weingarten, MD, MPH, FACC
 
Keynote Lecture: Sensationalizing Clinical Trials: ORBITA Trial, A Case in Point
Paul S. Teirstein, MD, FACC

The Physician Entrepreneur: Is There a Role?
Todd Brinton, MD

SESSION XI: New Devices for Heart Failure

Neurostimulation for the Treatment of HFrEF:  Vagal Nerve Stimulation, Spinal Cord Stimulation, Renal Denervation, and Baroreflex Activation Therapy
Luanda Grazette, MD, MPH, FACC
           
Interatrial Shunting for the Treatment of Heart Failure Across the Spectrum of LVEF – HFrEF, HFmrEF, and HFpEF
Neal Eigler, MD, FACC

Session XIII: Controversies in Advanced Heart Failure

Heart Transplantation in 2019: Challenges and Opportunities
Michelle Kittleson, MD, PhD, FACC
 
Use of RNA Interference (RNAi) Therapies in Cardiac Amyloidosis: Salvation?
Jignesh Patel, MD, PhD, FACC
 
Debate: Xeno vs. TAH: Which is the Future? Alternatives to Heart Transplantations
• Xenotransplantaton
Lawrence S.C. Czer, MD, FACC
• Total Artificial Heart
Fardad Esmailian, MD

Session XIV: Understanding Pathophysiology of Endurance Sports       


Exercise Optimization
Matthew T. Wheeler, MD, PhD

Session XV: Advanced Technology in CVD Management: Improving Outcomes and Quality
 
The Doctor Will ‘See’ You Now: Incorporating Handheld Ultrasound Into Daily Cardiology Care
Ilan Kedan, MD, MPH, FACC
For more information, please contact:
Promedica International CME
300 Carlsbad Village Dr., Ste 108A-326 | Carsbad | CA | 92008
Phone: 760-720-2263 | Fax: 760-720-6263
Email: Rebecca Law, rlaw@promedicacme.com
  • Home
  • CME